BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 9262248)

  • 1. Estrogen-progestin replacement therapy and endometrial cancer.
    Pike MC; Peters RK; Cozen W; Probst-Hensch NM; Felix JC; Wan PC; Mack TM
    J Natl Cancer Inst; 1997 Aug; 89(15):1110-6. PubMed ID: 9262248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer.
    Pike MC; Ross RK
    Steroids; 2000; 65(10-11):659-64. PubMed ID: 11108873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy.
    Chubak J; Doherty JA; Cushing-Haugen KL; Voigt LF; Saltzman BS; Hill DA; Beresford SA; Weiss NS
    Cancer Causes Control; 2007 Nov; 18(9):1001-7. PubMed ID: 17653829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of endometrial cancer following estrogen replacement with and without progestins.
    Weiderpass E; Adami HO; Baron JA; Magnusson C; Bergström R; Lindgren A; Correia N; Persson I
    J Natl Cancer Inst; 1999 Jul; 91(13):1131-7. PubMed ID: 10393721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
    Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer.
    Doherty JA; Cushing-Haugen KL; Saltzman BS; Voigt LF; Hill DA; Beresford SA; Chen C; Weiss NS
    Am J Obstet Gynecol; 2007 Aug; 197(2):139.e1-7. PubMed ID: 17689625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
    Ross RK; Paganini-Hill A; Wan PC; Pike MC
    J Natl Cancer Inst; 2000 Feb; 92(4):328-32. PubMed ID: 10675382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous combined hormone replacement therapy and risk of endometrial cancer.
    Hill DA; Weiss NS; Beresford SA; Voigt LF; Daling JR; Stanford JL; Self S
    Am J Obstet Gynecol; 2000 Dec; 183(6):1456-61. PubMed ID: 11120510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy.
    McGonigle KF; Karlan BY; Barbuto DA; Leuchter RS; Lagasse LD; Judd HL
    Gynecol Oncol; 1994 Oct; 55(1):126-32. PubMed ID: 7959253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term postmenopausal hormone therapy and endometrial cancer.
    Razavi P; Pike MC; Horn-Ross PL; Templeman C; Bernstein L; Ursin G
    Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):475-83. PubMed ID: 20086105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?
    Trabert B; Wentzensen N; Yang HP; Sherman ME; Hollenbeck AR; Park Y; Brinton LA
    Int J Cancer; 2013 Jan; 132(2):417-26. PubMed ID: 22553145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort.
    Lacey JV; Leitzmann MF; Chang SC; Mouw T; Hollenbeck AR; Schatzkin A; Brinton LA
    Cancer; 2007 Apr; 109(7):1303-11. PubMed ID: 17315161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States).
    Newcomb PA; Trentham-Dietz A
    Cancer Causes Control; 2003 Mar; 14(2):195-201. PubMed ID: 12749724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer.
    Reed SD; Voigt LF; Beresford SA; Hill DA; Doherty JA; Weiss NS
    Am J Obstet Gynecol; 2004 Oct; 191(4):1146-51. PubMed ID: 15507934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone replacement therapy and the risk of endometrial cancer: A systematic review.
    Sjögren LL; Mørch LS; Løkkegaard E
    Maturitas; 2016 Sep; 91():25-35. PubMed ID: 27451318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone replacement therapy and endometrial cancer risk: a meta-analysis.
    Grady D; Gebretsadik T; Kerlikowske K; Ernster V; Petitti D
    Obstet Gynecol; 1995 Feb; 85(2):304-13. PubMed ID: 7824251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: estrogen-progestin replacement therapy and endometrial cancer.
    McKnight B; Voigt LF; Beresford SA; Weiss NS
    J Natl Cancer Inst; 1998 Jan; 90(2):164-6. PubMed ID: 9450582
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women.
    Archer DF
    Menopause; 2001; 8(4):245-51. PubMed ID: 11449081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmenopausal hormone replacement therapy use and risk of endometrial cancer in Japanese women.
    Mizunuma H; Honjo H; Aso T; Urabe M; Ohta H; Kobayashi S; Sagara Y; Sanada M; Tanaka K; Dobashi K; Hayashi K; Ohama K
    Climacteric; 2001 Dec; 4(4):293-8. PubMed ID: 11770185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
    Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
    Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.